Lineage Cell Therapeutics has announced the pricing of a registered direct offering of up to $66 million. The company has already secured $30 million in this offering, with shares down 18.9% pre-market. Forte Biosciences, Inc. announced an oversubscribed $53 million private placement from leading healthcare institutional investors to advance its FB102 program across autoimmune indications, with shares up 150% pre-market. Cidara Therapeutics has secured a $105 million private placement led by Venrock Healthcare.